The risk factors for HCC in patients with SVR receiving interferon treatment are age, male gender, progression of liver fibrosis and steatosis, low serum cholesterol level, hyperglycemia, and higher ALT and alpha-fetoprotein levels, although we did not measure alpha-fetoprotein levels in all patients. This evidence concerns the gene AFP and hepatocellular carcinoma.